Total skin electron beam therapy as palliative treatment for cutaneous manifestations of advanced, therapy-refractory cutaneous lymphoma and leukemia

Radiation Oncology

Marc Bischof¹  Klaus Herfarth¹  Jürgen Debus¹  Frank Hensley¹  Matthias Uhl¹  Nathalie Rochet¹  Felix Zwicker¹  Henrik Hauswald¹ 

[1] Department of Radiation Oncology, University of Heidelberg, INF 400, Heidelberg, 69120, Germany

关键词: Leukemia;    Lymphoma;    Cutaneous lymphoma;    CTCL;    Irradiation;    Radiotherapy;    TSEBT;   

Others  :  1228578
DOI  :  10.1186/1748-717X-7-118

 received in 2012-03-30, accepted in 2012-06-18,  发布年份 2012

【 摘 要 】

Background

To retrospectively access the outcome and toxicity of a total skin electron beam therapy (TSEBT) in patients with cutaneous lymphoma (CL) or leukemia.

Patients and methods

Treatment results of 25 patients (median age 63 years; 5 female, 20 male) with cutaneous manifestations of advanced and therapy-refractory CL (n = 21; T-cell lymphomas n = 18, B-cell lymphomas n = 3) stage IIB-IV or leukemia (n = 4; AML n = 2, CLL n = 1, PDC n = 1) treated between 1993 and 2010 were reviewed. All patients were symptomatic. The median total dose was 29Gy, applied in 29 fractions of median 1 Gy each.

Results

The median follow-up was 10 months. Palliation was achieved in 23 patients (92%). A clinical complete response was documented in 13 (52%) and a partial response in 10 patients (40%). The median time to skin progression was 5 months (range 1–18 months) and the actuarial one-year progression-free survival 35%. The median overall survival (OS) after the initiation of TSEBT was 10 months (range 1–46 months) and the actuarial one-year OS 45%. TSEBT related acute adverse events (grade 1 or 2) were observed in all patients during the treatment period. An acute grade 3 epitheliolysis developed in eight patients (32%). Long-term adverse events as a hyperpigmentation of the skin (grade 1 or 2) were documented in 19 patients (76%), and a hypohidrosis in seven patients (28%).

Conclusion

For palliation of symptomatic cutaneous manifestations of advanced cutaneous lymphoma or leukemia, total skin electron beam therapy is an efficient and well tolerated considerable treatment option.

【 授权许可】

   
2012 Hauswald et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1 .

Figure 2 .

Figure 3 .

Figure 4 .

【 参考文献 】

• [1]Bradford PT, Devesa SS, Anderson WF, Toro JR: Cutaneous lymphoma incidence patterns in the United States: a population-based study of 3884 cases. Blood 2009, 113:5064-5073.
• [2]Willemze R, Jaffe ES, Burg G, Cerroni L, Berti E, Swerdlow SH, Ralfkiaer E, Chimenti S, Diaz-Perez JL, Duncan LM, Grange F, Harris NL, Kempf W, Kerl H, Kurrer M, Knobler R, Pimpinelli N, Sander C, Santucci M, Sterry W, Vermeer MH, Wechsler J, Whittaker S, Meijer CJLM: WHO-EORTC classification for cutaneous lymphomas. Blood 2005, 105:3768-3785.
• [3]Turner JJ, Morton LM, Linet MS, Clarke CA, Kadin ME, Vajdic CM, Monnereau A, Maynadié M, Chiu BC-H, Marcos-Gragera R, Costantini AS, Cerhan JR, Weisenburger DD: InterLymph hierarchical classification of lymphoid neoplasms for epidemiologic research based on the WHO classification (2008): update and future directions. Blood 2010, 116:e90-e98.
• [4]Olsen E, Vonderheid E, Pimpinelli N, Willemze R, Kim Y, Knobler R, Zackheim H, Duvic M, Estrach T, Lamberg S, Wood G, Dummer R, Ranki A, Burg G, Heald P, Pittelkow M, Bernengo M-G, Sterry W, Laroche L, Trautinger F, Whittaker S: Revisions to the staging and classification of mycosis fungoides and Sezary syndrome: a proposal of the International Society for Cutaneous Lymphomas (ISCL) and the cutaneous lymphoma task force of the European Organization of Research and Treatment of Cancer (EORTC). Blood 2007, 110:1713-1722.
• [5]Agis H, Weltermann A, Fonatsch C, Haas O, Mitterbauer G, Müllauer L, Schreiber S, Schwarzinger I, Juretzka W, Valent P, Jäger U, Lechner K, Geissler K: A comparative study on demographic, hematological, and cytogenetic findings and prognosis in acute myeloid leukemia with and without leukemia cutis. Ann Hematol 2002, 81:90-95.
• [6]Liu PI, Ishimaru T, McGregor DH, Okada H, Steer A: Autopsy study of granulocytic sarcoma (chloroma) in patients with myelogenous leukemia, Hiroshima-Nagasaki 1949–1969. Cancer 1973, 31:948-955.
• [7]Podgorsak EB, Pla C, Pla M, Lefebvre PY, Heese R: Physical aspects of a rotational total skin electron irradiation. Med Phys 1983, 10:159-168.
• [8]Kumar PP, Good RR, Jones EO: Rotational total skin electron beam therapy. Strahlenther Onkol 1988, 164:73-78.
• [9]Funk A, Hensley F, Krempien R, Neuhof D, Van Kampen M, Treiber M, Roeder F, Timke C, Herfarth K, Helmbold P, Debus J, Bischof M: Palliative total skin electron beam therapy (TSEBT) for advanced cutaneous T-cell lymphoma. Eur J Dermatol 2008, 18:308-312.
• [10]Rubin CM, Arthur DC, Meyers G, McClain KL, Kim TH, Woods WG: Leukemia cutis treated with total skin irradiation. Cancer 1985, 55:2649-2652.
• [11]Pepek JM, Paulino AC, Briones MA, Marcus RB, Esiashvili N: Role of total skin electron beam therapy for leukemia cutis in pediatric patients. Pediatr Blood Cancer 2008, 50:1054-1055.
• [12]Bao Q, Hrycushko BA, Dugas JP, Hager FH, Solberg TD: A technique for pediatric total skin electron irradiation. Radiat Oncol 2012, 7:40. BioMed Central Full Text
• [13]Bakst R, Wolden S, Yahalom J: Radiation therapy for chloroma (granulocytic sarcoma). Int J Radiat Oncol Biol Phys 2012, 82:1816-1822.
• [14]Harrison C, Young J, Navi D, Riaz N, Lingala B, Kim Y, Hoppe R: Revisiting low-dose total skin electron beam therapy in mycosis fungoides. Int J Radiat Oncol Biol Phys 2011, 81:e651-e657.
• [15]Kamstrup MR, Lindahl LM, Gniadecki R, Iversen L, Skov L, Petersen PM, Loft A, Specht L: Low-dose total skin electron beam therapy as a debulking agent for cutaneous T-cell lymphoma: an open-label prospective phase II study. Br J Dermatol 2012, 166:399-404.
• [16]Lindahl LM, Kamstrup MR, Petersen PM, Wirén J, Fenger-Grøn M, Gniadecki R, Iversen L, Specht L: Total skin electron beam therapy for cutaneous T-cell lymphoma: a nationwide cohort study from Denmark. Acta Oncol 2011, 50:1199-1205.
• [17]Navi D, Riaz N, Levin YS, Sullivan NC, Kim YH, Hoppe RT: The Stanford University experience with conventional-dose, total skin electron-beam therapy in the treatment of generalized patch or plaque (T2) and tumor (T3) mycosis fungoides. Arch Dermatol 2011, 147:561-567.
• [18]Chinn DM, Chow S, Kim YH, Hoppe RT: Total skin electron beam therapy with or without adjuvant topical nitrogen mustard or nitrogen mustard alone as initial treatment of T2 and T3 mycosis fungoides. Int J Radiat Oncol Biol Phys 1999, 43:951-958.
• [19]Neelis KJ, Schimmel EC, Vermeer MH, Senff NJ, Willemze R, Noordijk EM: Low-dose palliative radiotherapy for cutaneous B- and T-cell lymphomas. Int J Radiat Oncol Biol Phys 2009, 74:154-158.